摘要
2019年最新发布的全球癌症发病率和死亡率统计中,肺癌依然为发病率和死亡率第一的恶性肿瘤。非小细胞肺癌(non-small cell lung cancer,NSCLC)发现时大多已属晚期,失去了手术机会。含铂双药化疗已成为晚期NSCLC治疗的主要方法,患者中位生存期为8~10个月。由于化疗有效率不高,患者中位生存时间短,因此,寻找新的药物成为临床晚期肺癌治疗的棘手问题。贝伐珠单抗是抗血管生成药物,它的出现为晚期肺癌患者的治疗带来了希望,与其他治疗的联合应用更新了传统含铂双药一线化疗的治疗模式。随着分子生物学的发展,科学家发现多条通路之间均有联系,如表皮生长因子受体和血管内皮生长因子之间、血管内皮生长因子和程序性死亡蛋白-1/程序性死亡蛋白配体-1之间都会相互影响。如今,抗血管生成药物与靶向药物、免疫抑制剂之间的联合应用刚刚起步,很多数据并不成熟,本文就贝伐珠单抗与免疫治疗和靶向治疗联合应用的研究进展做一总结。
In the latest global cancer morbidity and mortality statistics released in 2019,lung cancer is still the number one malignancy in morbidity and mortality.Most non-small cell lung cancer(NSCLC)patients are found to be in advanced stages and have lost the opportunity for surgery.Platinum-based chemotherapy has become the main treatment method for patients with advanced NSCLC,with a median survival period of 8 to 10 months.Due to the low efficiency of chemotherapy and the short median survival time,finding new therapeutic drugs has become a thorny problem in clinical treatment of advanced lung cancer.The emergence of bevacizumab has brought hope to the treatment of patients with advanced lung cancer.It is an angiogenesis inhibitor,and its combined application with other treatments has updated the model of traditional first-line platinum-based chemotherapy.With the development of molecular biology,scientists have discovered that there are many links between multiple pathways,such as epidermal growth factor receptor(EGFR)and vascular endothelial growth factor(VEGF),VEGF and programmed death-1(PD-1)/programmed death ligand-1(PD-L1)will interact with each other.Nowadays,the joint use of anti-vascular drugs,targeted drugs,and immunosuppressants has just begun,and many data are not mature.Therefore,this article will explain the cooperation and challenges between bevacizumab and the era of immunotherapy and precision targeted therapy.
作者
马跃
刘明辉
陈军
Ma Yue;Liu Minghui;Chen Jun(Department of Lung Cancer Surgery,Tianjin Medical University General Hospital,Tianjin 300052,China;Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment,Tianjin Lung Cancer Institute,Tianjin 300052,China)
出处
《中国医学前沿杂志（电子版）》
2020年第7期17-23,共7页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
国家自然科学基金项目(81773207)
天津市科技支撑计划重点项目(19YFZCSY00040)
天津市拔尖创新团队基金(TJTZJHGCCCXCYTD-2-6)。
关键词
肺癌
贝伐珠单抗
化疗
血管内皮生长因子受体
免疫治疗
Lung cancer
Bevacizumab
Chemotherapy
Vascular endothelial growth factor receptor
Immunotherapy
